Figure 2A. UAGT/UCre levels were significantly increased in hypertensive patients not treated with RAS blockers (RASB) compared with normotensive subjects 56. Patients treated with RAS blockers exhibited a marked attenuation of this augmentation.
*, p < 0.05 vs. Normotensive. †, p < 0.05 vs. HTN - RASB.
Figure 2B. Log(UAGT/UCre) levels in chronic kidney disease (CKD) patients and in healthy volunteers 58. Log(UAGT/UCre) levels were significantly increased in CKD patients compared with that in control subjects.